Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer from breast punch Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Two targeted therapies- lapatinib plus trastuzumab - are better than one in the fight against HER2-positive metastatic breast cancer. These two targeted therapies against HER2, sort of a 'one-two punch', conveyed a more than four month significant improvement in survival when compared to lapatinib alone. Official San Antonio Breast Cancer Symposium press conference.nnnnWatch Dr Blackwell speaking to ecancertv about the research she is presenting at SABCS 2009.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)